CD19 and non-Hodgkin lymphoma: Considering the immunological benefits of decitabine (DAC) observed in enhancing CD19 CAR T cell activity against B-ALL and NHL, we have included DAC in the lymphodepletion regimen for adult patients with B cell neoplasms undergoing CD19 CAR T cell therapy.11